<DOC>
	<DOCNO>NCT00000885</DOCNO>
	<brief_summary>Group A : To compare time confirm virologic failure ( 2 consecutive plasma HIV-RNA concentration 500 copies/ml ) treatment arm : abacavir ( ABC ) placebo combination zidovudine ( ZDV ) , lamivudine ( 3TC ) , indinavir ( IDV ) . To evaluate safety tolerability treatment arm . [ AS PER AMENDMENT 06/16/99 : To compare time confirm treatment failure , permanent discontinuation treatment , death treatment arm . ] [ AS PER AMENDMENT 12/27/01 : Groups B , C , D complete follow-up March 4 , 1999 . Therefore , information pertinent Group A applicable . ] Group B : To compare proportion patient achieve plasma HIV-1 RNA concentration 500 copies/ml , assessed standard Roche Amplicor assay Week 16 , compare absolute change plasma HIV-1 RNA concentration Week 16 across treatment arm : ABC approve nucleoside analog nelfinavir ( NFV ) placebo combination efavirenz ( EFV ) adefovir dipivoxil . To compare safety tolerability treatment arm . Group C : To monitor plasma HIV-1 RNA trajectory time determine time confirm plasma HIV-1 RNA concentration 2,000 copies/ml 2 consecutive determination patient treat ZDV stavudine ( d4T ) plus 3TC IDV . Group D : To evaluate plasma HIV-1 RNA responses Weeks 16 48 . To evaluate safety tolerability treatment arm : ABC , EFV , adefovir dipivoxil , NFV . This study explore new treatment option ACTG 320 enrollee ( , need , limited number non-ACTG 320 volunteer ) receive ZDV ( d4T ) plus 3TC IDV currently exhibit range virologic response . By divide study corresponding , nonsequential cohort ( Groups A , B , C , D ) , different approach evaluate virologic success , i.e. , undetectable plasma HIV-1 RNA level , virologic failure , i.e. , plasma HIV-1 RNA level 500 copies/ml [ AS PER AMENDMENT 12/27/01 : 200 copies/ml ] , explore maintain long-term follow-up ACTG 320 patient . [ AS PER AMENDMENT 12/27/01 : Groups B , C , D complete follow-up March 4 , 1999 . Therefore , information pertinent Group A applicable . This study examine question whether intensification therapy prolong virologic benefit individual whose plasma HIV-1 RNA concentration limit assay detection ZDV ( d4T ) plus 3TC plus IDV . ]</brief_summary>
	<brief_title>Treatment Success Failure HIV-Infected Subjects Receiving Indinavir Combination With Nucleoside Analogs : A Rollover Study ACTG 320</brief_title>
	<detailed_description>This study explore new treatment option ACTG 320 enrollee ( , need , limited number non-ACTG 320 volunteer ) receive ZDV ( d4T ) plus 3TC IDV currently exhibit range virologic response . By divide study corresponding , nonsequential cohort ( Groups A , B , C , D ) , different approach evaluate virologic success , i.e. , undetectable plasma HIV-1 RNA level , virologic failure , i.e. , plasma HIV-1 RNA level 500 copies/ml [ AS PER AMENDMENT 12/27/01 : 200 copies/ml ] , explore maintain long-term follow-up ACTG 320 patient . [ AS PER AMENDMENT 12/27/01 : Groups B , C , D complete follow-up March 4 , 1999 . Therefore , information pertinent Group A include . This study examine question whether intensification therapy prolong virologic benefit individual whose plasma HIV-1 RNA concentration limit assay detection ZDV ( d4T ) plus 3TC plus IDV . ] Rollover patient ACTG 320 give enrollment priority permit enroll 4 study group ; non-ACTG patient permit enroll Groups A B accrual objective meet ACTG 320 patient . GROUP A : Patients screen plasma HIV-1 RNA concentration 500 copies/ml randomize 1 2 treatment arm stratify accord participation ACTG 320 ( original randomization IDV versus open-label IDV ) . The 2 treatment arm follow : ARM A1 : IDV plus ZDV ( d4T ) plus 3TC plus ABC . ARM A2 : IDV plus ZDV ( d4T ) plus 3TC plus ABC placebo . Patients achieve plasma HIV-1 RNA level 500 copies/ml 2 consecutive determination may continue assigned arm blind fashion , seek best alternative therapy select local investigator primary care physician . GROUP B : Nonnucleoside reverse transcriptase inhibitor ( NNRTI ) -naive patient plasma HIV-1 RNA plasma concentration 500 copies/ml randomize 1 4 treatment arm stratify plasma HIV-1 RNA concentration ( versus 15,000 RNA copies/ml ) participation ACTG 320 ( original randomization IDV versus open-label IDV ) . The treatment arm follow : ARM B1 : ABC plus EFV plus adefovir dipivoxil plus NFV . ARM B2 : ABC plus EFV plus adefovir dipivoxil plus NFV placebo . ARM B3 : 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) ( 1 2 tolerate ) ( choose ZDV , 3TC , d4T , didanosine [ ddI ] ) plus EFV plus adefovir dipivoxil plus NFV . ARM B4 : 2 NRTIs ( 1 2 tolerate ) ( choose ZDV , 3TC , d4T , ddI ) plus EFV plus adefovir dipivoxil plus NFV placebo . GROUP C : NNRTI-naive patient plasma HIV-1 RNA concentration 500-2,000 copies/ml screen may elect randomized treatment arm Group B continue current ACTG 320 regimen follow : ARM C : ZDV ( d4T ) plus 3TC plus IDV . Patients elect treatment randomize Group B plasma HIV-1 RNA concentration confirm 2,000 copy . GROUP D : NNRTI-experienced , ACTG 320 patient screen plasma HIV-1 RNA concentration 500 copies/ml receive open-label treatment follow : ARM D : ABC plus EFV plus adefovir dipivoxil plus NFV . [ AS PER AMENDMENT 06/29/98 : Enrollment Group B close accrual . Group A patient HIV-1 RNA 200 copies/ml 2 consecutive determination may continue assign treatment seek best alternative antiretroviral therapy , may include access ABC . Group B patient plasma HIV-1 RNA 500 copies/ml may continue assign treatment seek best available antiretroviral therapy , may include access ABC , EFV , adefovir dipivoxil L-carnitine supplementation . Group C patient HIV-1 RNA level 2,000 copies/ml Group D patient level 500 copies/ml may longer randomize treatment arm Group B . Such patient may continue assign treatment seek best available therapy , may include access therapy per Group B patient . ] [ AS PER AMENDMENT 06/16/99 : Study treatment Groups B , C , D complete . Group A patient confirm plasma HIV-2 endpoint remain study may access ABC study . ] [ AS PER AMENDMENT 12/27/01 : With Version 4.0 protocol , many metabolic assessment cardiovascular risk assessment repeat , self-reported questionnaire body shape change add . In addition , investigation effect long-term IDV pyuria/hematuria add , well study HIV-1 RNA peripheral blood mononuclear cell ( PBMCs ) . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Chemoprophylaxis Pneumocystis carinii pneumonia patient CD4 cell count 200 cells/mm3 less . Allowed : Treatment , maintenance , chemoprophylaxis , include topical and/or oral antifungal agent unless otherwise exclude protocol . All antibiotic clinically indicate , unless otherwise exclude protocol . Systemic corticosteroid use 21 day less acute problem medically indicate . Chronic corticosteroid use permit , unless within physiologic replacement level . Study team must contact instance . rEPO GCSF medically indicate . Regularly prescribed medication [ AS PER AMENDMENT 06/29/98 : alternative , FDAapproved antiretrovirals supply study ] [ AS PER AMENDMENT 12/27/01 : unapproved antiretrovirals available expanded access ( permanently discontinue randomize study treatment ) ] , antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , megestrol acetate , testosterone , medication otherwise exclude protocol , medically indicate . [ AS PER AMENDMENT 12/27/01 : Supplemental ] alternative therapy vitamin , acupuncture , visualization technique . Recommended alternative agent chemoprophylaxis Mycobacterium avium complex patient randomize EFV Group B D : clarithromycin azithromycin . Patients must : HIV1 infection document license ELISA test kit confirm either Western Blot , HIV culture , HIV antigen , plasma HIV1 RNA , second antibody test method ELISA time prior study entry . NonACTG patient : Documented CD4 cell count 200 cells/mm3 less time initiation ZDV ( d4T ) plus 3TC plus IDV . Signed , inform consent parent legal guardian patient 18 year age . Prior Medication : Required : NonACTG 320 patient : At least 3 month prior therapy ZDV ( d4T ) plus 3TC plus IDV continue receipt ZDV ( d4T ) plus 3TC plus IDV enrollment . IDV 3TC must initiate concurrently . ACTG patient : Randomization ZDV ( d4T ) plus 3TC plus IDV combination arm receipt openlabel prior unblinding maintenance treatment participation ACTG 320 . Group D : Prior NNRTIexposure . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Unexplained temperature 38.5 C 7 day chronic diarrhea , define 3 liquid stool per day persist 15 day , within 30 day prior study treatment . AIDSrelated malignancy , minimal Kaposi 's sarcoma require systemic chemotherapy . Minimal Kaposi 's sarcoma define 5 few cutaneous lesion visceral disease tumorassociated edema require systemic therapy . Documented suspect acute hepatitis within 30 day prior study entry , irrespective laboratory value . Concurrent Medication : Excluded : All antiretroviral therapy study [ AS PER AMENDMENT 06/16/99 : provide ] medication , [ AS PER AMENDMENT 06/16/99 : unless approve protocol chair ] [ AS PER AMENDMENT 12/27/01 : original randomized treatment . ] Rifabutin rifampin . Investigational agent without specific approval protocol chair . Systemic cytotoxic chemotherapy . Oral ketoconazole itraconazole . NOTE : Itraconazole may permit Group B Group D patient fluconazole option . Terfenadine , astemizole , cisapride , triazolam , midazolam , amiodarone , quinine , ergot derivative , isotretinoin , [ AS PER AMENDMENT 12/27/01 : pimozide , St.John 's Wort , milk thistle . ] [ AS PER AMENDMENT 12/27/01 : Concomitant use lovastatin simvastatin recommend potential drug interaction . Pravastatin atorvastatin may use consultation Study Team . ] To avoid : Herbal medication . Prior Medication : Excluded : Any prior protease inhibitor therapy indinavir . Interferons , interleukin , HIV vaccine within 30 day prior study entry . Any experimental therapy within 30 day prior study entry . Rifampin , rifabutin , ketoconazole , itraconazole within 14 day study entry . NonACTG patient : Acute therapy infection medical illness within 14 day prior study therapy . NNRTI therapy prior study entry ( exception Group D ) . Recombinant erythropoietin ( rEPO ) , granulocyte colonystimulating factor ( GCSF , filgrastim ) , granulocytemacrophage colonystimulating factor ( GMCSF , sargramostim ) within 30 day prior study entry . Caution take consumption alcoholic beverage study medication .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Treatment Failure</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>